Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

07.03.18	Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference (Businesswire)
05.03.18	Dan R. Littman Elected to Pfizer’s Board of Directors (Businesswire)
05.03.18	ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With Tuberculosis (PR Newswire)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
02.03.18	Neofluidics Enters Collaboration With Pfizer - Quick Facts (RTTNews)
02.03.18	Neofluidics Announces Collaboration with Pfizer Inc. (PR Newswire)
27.02.18	Biotech Stocks Facing FDA Decision In March (RTTNews)
23.02.18	Pfizer Gets Positive CHMP Opinion For Mylotarg And Bosulif - Quick Facts (RTTNews)
23.02.18	Pfizer Updates On EMA Application For SUTENT (RTTNews)
23.02.18	Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma (Businesswire)
23.02.18	Albert Bourla Elected to Pfizer’s Board of Directors (Businesswire)
15.02.18	Merck: Phase III JAVELIN Lung 200 Trial With Avelumab Fails To Meet Endpoint (RTTNews)
14.02.18	Pfizer Receives Breakthrough Therapy Designation For PF-04965842 - Quick Facts (RTTNews)
14.02.18	Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis (Businesswire)
13.02.18	Success Of Mow N' Stow® Technology Leads To Expanded Offering (PR Newswire)
12.02.18	U.S., EU, Japan Accept Regulatory Submissions For Review Of Pfizer's Lorlatinib (RTTNews)
08.02.18	ViiV Files Patent Infringement Lawsuit Against Gilead Sciences On Bictegravir (RTTNews)
06.02.18	Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall (RTTNews)
05.02.18	Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer (Businesswire)
05.02.18	Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
05.02.18	Bloomberg: Glaxo, Reckitt Submit Bids For Pfizer's Consumer Business Unit (RTTNews)
30.01.18	IIROC Trading Resumption - PERU (PR Newswire)
30.01.18	Pfizer Q4 Results Beat Estimates; Issues Upbeat FY18 Outlook (RTTNews)
30.01.18	Pfizer Inc. Earnings Climb In Q4 (RTTNews)
30.01.18	PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS (Businesswire)
24.01.18	Pfizer: Potential Biosimilar To Rituxan Meets Primary Endpoint - Quick Facts (RTTNews)
24.01.18	Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera® (Businesswire)
22.01.18	Some Branded Drugs Going Generic In 2018 (RTTNews)
16.01.18	Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics (RTTNews)
16.01.18	The Race To Find A Treatment For NASH (RTTNews)
11.01.18	Novartis Names Elizabeth Barrett CEO, Novartis Oncology - Quick Facts (RTTNews)
08.01.18	Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents (Businesswire)
08.01.18	Pfizer Establishes New Partnering Model for Early-Stage Academic Research (Businesswire)
08.01.18	Pfizer Ends Alzheimer's And Parkinson's Research; To Cut 300 Jobs (RTTNews)
07.01.18	New Drugs Approved In December (RTTNews)
04.01.18	Berkeley Lights Announces Research Collaboration and License Agreement with Pfizer (PR Newswire)
04.01.18	Arvinas Sees $830 Mln Upfront, Potential Milestone Payments In Deal With Pfizer (RTTNews)
04.01.18	Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates (PR Newswire)
03.01.18	Sangamo, Pfizer Collaborate On Zinc Finger Protein Gene Therapy For ALS (RTTNews)
03.01.18	Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS (PR Newswire)
27.12.17	Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference (Businesswire)
24.12.17	It's Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed Yet Again (RTTNews)
22.12.17	Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan (RTTNews)
21.12.17	FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma (PR Newswire)
21.12.17	Pfizer Inc. Announces Pricing and Early Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents (Businesswire)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
19.12.17	U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) (Businesswire)
19.12.17	Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	76.62	0.39 %	K V
Part Grp Hldg	1’271.50	0.36 %	K V
Holcim	89.08	0.25 %	K V
Logitech Intl	74.82	-0.05 %	K V
Lonza Grp	540.60	-0.15 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	223.10	-1.37 %	K V
Nestle	74.10	-1.49 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’961.00	-2.46 %	K V

mehr

07:18		Roche-Aktie: Roche vermeldet Forschungsrückschlag - Mittel verfehlt primären Endpunkt
18.12.24		Dow Jones-Handel aktuell: Dow Jones beendet den Mittwochshandel mit Verlusten
18.12.24		Zuversicht in Frankfurt: Zum Ende des Mittwochshandels Pluszeichen im TecDAX
18.12.24		Börse Zürich in Rot: SPI schliesst in der Verlustzone
18.12.24		Pluszeichen in Europa: STOXX 50 letztendlich fester
18.12.24		Handel in Europa: Euro STOXX 50 präsentiert sich letztendlich fester
18.12.24		Freundlicher Handel in London: FTSE 100 notiert zum Ende des Mittwochshandels im Plus
18.12.24		Aufschläge in Frankfurt: SDAX steigt zum Handelsende

07:18

Roche-Aktie: Roche vermeldet Forschungsrückschlag - Mittel verfehlt primären Endpunkt

18.12.24

Dow Jones-Handel aktuell: Dow Jones beendet den Mittwochshandel mit Verlusten

18.12.24

Zuversicht in Frankfurt: Zum Ende des Mittwochshandels Pluszeichen im TecDAX

18.12.24

Börse Zürich in Rot: SPI schliesst in der Verlustzone

18.12.24

Pluszeichen in Europa: STOXX 50 letztendlich fester

18.12.24

Handel in Europa: Euro STOXX 50 präsentiert sich letztendlich fester